Table 4 Univariate Cox regression analysis of factors associated with survival

• Female

113 (72.9)

1.0

–

0.36

• Male

115 (71)

0.89

0.68,1.15

• Age < 60

86 (68.3)

1.0

–

0.96

• Age ≥ 60

142 (74.4)

1.01

0.77,1.32

• Married

153 (69.6)

1.0

–

0.62

• Divorced

19 (82.6)

1.30

0.81,2.10

• Widowed

33 (76.7)

1.03

0.71,1.51

• Single

23 (74.2)

1.23

0.80,1.91

• Head and neck cancer

26 (60.5)

1.0

–

0.26

• Breast cancer

16 (72.7)

1.40

0.75,2.62

• Primary lung cancer

41 (71.9)

1.09

0.66,1.78

• Gastrointestinal cancer

99 (78)

1.51

0.98,2.34

• Genitourinary cancer

24 (70.6)

1.07

0.62,1.87

• Others

22 (67.7)

1.15

0.65,2.03

 Evidence of metastases at consultation

204 (72.3)

1.0

–

0.33

 No metastases

24 (68.5)

0.81

0.53,1.24

• ≤ 30

113 (86.9)

1.0

–

<0.01

• 40–60

73 (71.6)

0.27

0.20,0.38

• ≥ 70

30 (46.2)

0.11

0.07,0.16

• No home visit

151 (68.6)

1.0

–

0.04

• Home visit

77 (79.4)

0.75

0.57,0.99

• No palliative care clinic visit

154 (80.6)

1.0

–

<0.01

• Palliative care clinic visit

74 (58.7)

0.32

0.24,0.43

• No hospital admission

81 (64.3)

1.0

–

<0.01

• Having hospital admission

147 (77)

2.03

1.54,2.67

• No chemotherapy

195 (76.5)

1.0

–

<0.01

• Receiving chemotherapy

33 (53.2)

0.32

0.22,0.46

• No radiotherapy

198 (73.9)

1.0

–

<0.01

• Receiving radiotherapy

30 (61.2)

0.53

0.36,0.78

• No surgery

220 (72.4)

1.0

–

0.12

• Receiving surgery

8 (61.5)

0.60

0.29,1.20

• ≤ 3

132 (67.7)

1.0

–

0.26

• > 3

95 (78.5)

1.16

0.89,1.52

• ≤ 30 mg/day

170 (69.7)

–

–

0.52

• > 30 mg/day

58 (79.5)

1.14

0.77,1.69